Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biopharmaceutical company Amicus Therapeutics
With that in mind, let's take a closer look at Amicus' business and see what CAPS investors are saying about the stock right now.
|Headquarters (Founded)||Cranbury, N.J. (2002)|
|Trailing-12-Month Revenue||$21.4 million|
|Management||Chairman/CEO John Crowley
CFO Daphne Quimi
|Return on Equity (Average, Past 3 Years)||(58.9%)|
|Cash/Debt||$69.5 million / $1.4 million|
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 32% of the 57 members who have rated Amicus believe the stock will underperform the S&P 500 going forward.
The critical catalyst for Amicus is topline data from study 11 of Amigal, now expected in Q3 2012 after multiple postponements. Aside from the delays, which are never a good sign, traders with long memories will remember that four years ago the stock fell from grace after the company reported phase II data for Amigal that did not bode well for competitiveness against Fabrazyme. ...
Amicus has a new partner in [GlaxoSmithKline] and phase II studies in progress for Amigal and AT2220 co-administered with enzyme replacement therapy, so study 11 isn't exactly do or die for the company. But with 56M in cash, there's a high likelihood of a large dilutive financing prior to the study 11 data readout, and also a substantial risk of trial failure. If the stock flirts with [$2.00] once again after that, I might take a renewed interest in a long position.
What do you think about Amicus, or any other stock for that matter? If you want to retire rich, you need to protect your portfolio from any undue risk. Staying away from dangerous stocks is crucial to securing your financial future, and on Motley Fool CAPS, thousands of investors are working every day to flag them. CAPS is 100% free, so get started!
Want to see how well (or not so well) the stocks in this series are performing? Follow the new TrackPoisedTo CAPS account.
Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Motley Fool newsletter services have recommended buying shares of GlaxoSmithKline. Try any of our Foolish newsletter services free for 30 days.
More from The Motley Fool
This Tiny Biotech Pins Hope on U.S. Approval
A new treatment of Fabry disease could be available in the United States as soon as 2018.
These Biotech Stocks Are Pricey, but Investors Can Still Buy Them
Sarepta Therapeutics and Amicus Therapeutics are tackling the unmet need for new treatments for rare conditions, and that could put them in position to generate market-beating returns.
Is Amicus Therapeutics Stock Still a Strong Buy?
Amicus' stock continues to benefit from its emerging rare disease pipeline and the industrywide upswing in biotech valuations this year.